Asia Pacific Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class (Anti-viral, Anti-Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route Of Administration (Oral, Parenteral, Topical, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)
The Asia Pacific infectious disease therapeutics market was valued at US$ 25,904.61 million in 2022 and is expected to reach US$ 37,415.07 million by 2030; it is estimated to register a CAGR of 4.7... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe Asia Pacific infectious disease therapeutics market was valued at US$ 25,904.61 million in 2022 and is expected to reach US$ 37,415.07 million by 2030; it is estimated to register a CAGR of 4.7% from 2022 to 2030.Growing Opportunities in Developing Nations Boost Asia Pacific Infectious Disease Therapeutics Market The growing incidence of infectious diseases is anticipated to increase the sales of infectious disease therapeutics drugs in developing countries. Asia Pacific has become an adaptable and business-friendly hub due to moderately fewer data requirements and stringent regulations. In addition, high investments in health research and life science in emerging countries play a key role in promoting the latest technologies in developing countries, which, in turn, supports the inclination toward infectious disease diagnosis and treatment. For instance, UNAIDS is calling for an investment of US$ 29 billion by 2025 to meet the needs of low- and middle-income countries in the AIDS response. Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in India and South Korea, are expected to witness lucrative opportunities in the future. This is owing to the high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improving infrastructure of healthcare; and growing medical tourism in these countries. Asia Pacific Infectious Disease Therapeutics Market Overview The Asia Pacific infectious disease therapeutics market is sub-segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR during the forecast period. The market in the region is expected to grow owing to rising global healthcare expenditure, increasing incidence of chronic and infectious diseases, and a growing geriatric population base. The infectious disease such as influenza, hepatitis B, and infectious diarrhea are common in China and typhoid, malaria, jaundice, tuberculosis, and AIDS in India. Influenza, hepatitis B, and infectious diarrhea are the three common infectious diseases in China. As stated by Frontiers Public Health, the winter peak of influenza coincided with the outbreak of COVID-19 in the country in 2021. According to the World Bank Country Director of China 2020, the country is at a high risk of infectious diseases due to its growing population, wildlife abundance, habitat fragmentation, and high livestock production levels. Considering the country's growing incidence of infectious diseases, the World Bank's Board of Executive Directors approved a US$ 300 million loan for the Emerging Infectious Diseases Prevention, Preparedness and Response Project. This will help it reduce the risk of zoonotic and other emerging health threats. Thus, the rising incidence of infectious diseases and measures taken to control these diseases are expected to boost the China infectious disease therapeutics market in the coming years. Asia Pacific Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million) Asia Pacific Infectious Disease Therapeutics Market Segmentation The Asia Pacific infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country. Based on drug class, the Asia Pacific infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022. In terms of indication, the Asia Pacific infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022. Based on route of administration, the Asia Pacific infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022. In terms of distribution channel, the Asia Pacific infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022. By country, the Asia Pacific infectious disease therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific infectious disease therapeutics market share in 2022. AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the Asia Pacific infectious disease therapeutics market. Table of ContentsTABLE OF CONTENTS1. Introduction 1.1 The Insight Partners Research Report Guidance 1.2 Market Segmentation 2. Executive Summary 2.1 Key Insights 3. Research Methodology 3.1 Coverage 3.2 Secondary Research 3.3 Primary Research 4. Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics 4.1 Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics 4.2 Market Drivers 4.2.1 Rising Prevalence of Infectious Disease 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics 4.3 Market Restraints 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects 4.4 Market Opportunities 4.4.1 Growing Opportunities in Developing Nations 4.4.2 Escalating Threat of Antibiotic Resistance 4.5 Future Trends 4.5.1 Rising Number of Product Approvals and Launches 4.6 Impact of Drivers and Restraints: 5. Infectious Disease Therapeutics Market - Asia Pacific Market Analysis 5.1 Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030 6. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Drug Class 6.1 Overview 6.2 Anti-Viral 6.2.1 Overview 6.2.2 Anti-viral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 6.3 Anti-bacterial 6.3.1 Overview 6.3.2 Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 6.4 Anti-fungal 6.4.1 Overview 6.4.2 Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 6.5 Others 6.5.1 Overview 6.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Indication 7.1 Overview 7.2 HIV 7.2.1 Overview 7.2.2 HIV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.3 Hepatitis 7.3.1 Overview 7.3.2 Hepatitis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.4 Tuberculosis 7.4.1 Overview 7.4.2 Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.5 Influenza 7.5.1 Overview 7.5.2 Influenza: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.6 HPV 7.6.1 Overview 7.6.2 HPV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.7 Others 7.7.1 Overview 7.7.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 8. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Route of Administration 8.1 Overview 8.2 Oral 8.2.1 Overview 8.2.2 Oral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 8.3 Parenteral 8.3.1 Overview 8.3.2 Parenteral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 8.4 Topical 8.4.1 Overview 8.4.2 Topical: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 8.5 Others 8.5.1 Overview 8.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 9. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Distribution Channel 9.1 Overview 9.2 Hospital Pharmacies 9.2.1 Overview 9.2.2 Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 9.3 Retail Pharmacies 9.3.1 Overview 9.3.2 Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 9.4 Others 9.4.1 Overview 9.4.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10. Asia Pacific Infectious Disease Therapeutics Market - Country Analysis 10.1 Asia Pacific Infectious Disease Therapeutics Market Overview 10.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country 10.1.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country 10.1.1.2 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.2.1 Overview 10.1.1.3 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.3.1 China: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.3.2 China: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.3.3 China: Infectious Disease Therapeutics Market Breakdown, by Route of Administration 10.1.1.3.4 China: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 10.1.1.4 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.4.1 Overview 10.1.1.5 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.5.1 Japan: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.5.2 Japan: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.5.3 Japan: Infectious Disease Therapeutics Market Breakdown, by Route of Administration 10.1.1.5.4 Japan: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 10.1.1.6 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.6.1 Overview 10.1.1.7 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.7.1 India: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.7.2 India: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.7.3 India: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration 10.1.1.7.4 India: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 10.1.1.8 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.8.1 Overview 10.1.1.9 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.9.1 Australia: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.9.2 Australia: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.9.3 Australia: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration 10.1.1.9.4 Australia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 10.1.1.10 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.10.1 Overview 10.1.1.11 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.11.1 South Korea: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.11.2 South Korea: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.11.3 South Korea: Infectious Disease Therapeutics Market Breakdown, by Route of Administration 10.1.1.11.4 South Korea: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 10.1.1.12 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.12.1 Overview 10.1.1.13 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.13.1 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.13.2 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.13.3 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Route of Administration 10.1.1.13.4 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 11. Infectious Disease Therapeutics Market-Industry Landscape 11.1 Overview 11.2 Growth Strategies in the Infectious Disease Therapeutics Market 11.3 Inorganic Growth Strategies 11.3.1 Overview 11.4 Organic Growth Strategies 11.4.1 Overview 12. Company Profiles 12.1 Pfizer Inc 12.1.1 Key Facts 12.1.2 Business Description 12.1.3 Products and Services 12.1.4 Financial Overview 12.1.5 SWOT Analysis 12.1.6 Key Developments 12.2 Gilead Sciences Inc 12.2.1 Key Facts 12.2.2 Business Description 12.2.3 Products and Services 12.2.4 Financial Overview 12.2.5 SWOT Analysis 12.2.6 Key Developments 12.3 F. Hoffmann-La Roche Ltd 12.3.1 Key Facts 12.3.2 Business Description 12.3.3 Products and Services 12.3.4 Financial Overview 12.3.5 SWOT Analysis 12.3.6 Key Developments 12.4 Shionogi & Co Ltd 12.4.1 Key Facts 12.4.2 Business Description 12.4.3 Products and Services 12.4.4 Financial Overview 12.4.5 SWOT Analysis 12.4.6 Key Developments 12.5 Bayer AG 12.5.1 Key Facts 12.5.2 Business Description 12.5.3 Products and Services 12.5.4 Financial Overview 12.5.5 SWOT Analysis 12.5.6 Key Developments 12.6 GSK Plc 12.6.1 Key Facts 12.6.2 Business Description 12.6.3 Products and Services 12.6.4 Financial Overview 12.6.5 SWOT Analysis 12.6.6 Key Developments 12.7 AbbVie Inc 12.7.1 Key Facts 12.7.2 Business Description 12.7.3 Products and Services 12.7.4 Financial Overview 12.7.5 SWOT Analysis 12.7.6 Key Developments 12.8 Merck & Co Inc 12.8.1 Key Facts 12.8.2 Business Description 12.8.3 Products and Services 12.8.4 Financial Overview 12.8.5 SWOT Analysis 12.8.6 Key Developments 12.9 Astellas Pharma Inc 12.9.1 Key Facts 12.9.2 Business Description 12.9.3 Products and Services 12.9.4 Financial Overview 12.9.5 SWOT Analysis 12.9.6 Key Developments 13. Appendix 13.1 About The Insight Partners
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(通信回線)の最新刊レポート
The Insight Partners 社の最新刊レポート
本レポートと同じKEY WORD(channel)の最新刊レポート
よくあるご質問The Insight Partners社はどのような調査会社ですか?The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/08 10:26 148.90 円 163.91 円 197.75 円 |